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Abstract
Background—Our objective was to describe time trends in selected pregnancy exposures in the 
National Birth Defects Prevention Study (NBDPS).
Methods—We analyzed data from the NBDPS, a multi-site case-control study of major birth 
defects, for mothers of live-born infants without birth defects (controls), with an expected date of 
delivery (EDD) from 1998 –2011. Mothers from the 10 participating centers across the United 
States were interviewed by phone between six weeks and two years after the EDD. We focused on 
maternal race/ethnicity and five maternal risk factors: obesity, use of folic acid-containing 
multivitamins, opioid analgesics, selective serotonin reuptake inhibitors (SSRIs), and loratadine 
because of their prevalence of use and some reports of associations with major birth defects. 
Prevalence time trends were examined using the Kendall’s τβ test statistic.
Results—The exposure trend analysis included 11,724 control mothers with EDDs from 1998–
2011. We observed a significant increase in obesity prevalence among control mothers, as well as 
use of SSRIs and loratadine. We also observed an increase in periconceptional use of folic acid-
containing multivitamins. Some of the time trends varied by race/ethnicity. No remarkable trend in 
the overall use of opioid analgesics was observed. The racial/ethnic distribution of mothers 
changed slightly during the study period.
Conclusions—Long-term, population-based case-control studies continue to be an effective 
way to assess exposure-birth defects associations and provide guidance to health care providers. 
Corresponding author: April Dawson, 1600 Clifton Road, MS-E86, Atlanta, GA 30333; telephone: 404-498-3912; fax: 
404-498-3550; isp3@cdc.gov. 
Disclosure statement: The authors report no conflict of interest.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position 
of the Centers for Disease Control and Prevention.
HHS Public Access
Author manuscript
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2016 August 
01.
Published in final edited form as:













However, investigators examining rare outcomes covering many years of data collection need to 
be cognizant of time trends in exposures.
INTRODUCTION
The National Birth Defects Prevention Study (NBDPS, 1997–2011) was a multi-site, case-
control study of major birth defects that collected data over a period of 14 birth years, which 
is an important strength of the study since it can be challenging to have an adequate study 
size for the investigation of birth defects. However, during this period there were some 
changes in the study protocol, such as revisions in the content of some of the telephone 
interview questions, as well as changes in the funded study centers resulting from open 
competitions for cooperative agreements. There were also changes outside of the control of 
the study, such as shifts in population demographics in a study area (Suro and Singer, 2002), 
Food and Drug Administration (FDA) warnings on the use of specific drugs during 
pregnancy, such as paroxetine (Food and Drug Administration, 2005), and recommendations 
by professional organizations on how to treat diseases in pregnancy, such as the American 
College of Obstetricians and Gynecologists (ACOG) guidelines on treating urinary tract 
infections (American College of Obstetricians and Gynecologists, 2011).
Because data are published throughout the course of a long-term study like the NBDPS, 
results from NBDPS publications could potentially affect the exposure prevalence in 
subsequent years of data collection. For example, the change in ACOG guidance for treating 
urinary tract infections during pregnancy cited a 2009 NBDPS publication in which 
researchers observed a significant association between some birth defects and first trimester 
use of nitrofurantoin or sulfonamides (Crider et al., 2009; American College of Obstetricians 
and Gynecologists, 2011). Papers published by other study groups during the study period, 
including those supporting or refuting NBDPS results, could also potentially impact 
exposure prevalence.
Because many internal and external factors may affect exposure prevalence, it is important 
for researchers involved in long-term studies to be aware of these factors and the potential 
impact on their analyses. In this paper, our objective was to examine time trends and review 
the published findings for maternal race-ethnicity and five selected risk factors – obesity; 
and use of folic acid-containing multivitamins, opioid analgesics, selective serotonin 
reuptake inhibitors (SSRIs), and loratadine.
METHODS
The NBDPS was a case-control study of birth defects that was a collaborative effort of the 
Centers for Birth Defects Research and Prevention in Arkansas, California, Georgia, Iowa, 
Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah. Institutional 
Review Boards at each site approved the study. Methods for recruitment of participants and 
data collection have been described in detail elsewhere (Yoon et al., 2001; Rasmussen et al., 
2003; Reefhuis et al., this issue). Cases included infants or fetuses with major birth defects 
identified through population-based surveillance systems at each site. Controls, i.e., live-
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born infants without major birth defects, were randomly selected using birth certificates or 
birth hospital records from the same ascertainment area and time period as the cases.
Maternal Race-Ethnicity and Selected Risk Factors
We selected maternal race-ethnicity and five risk factors for an analysis of time trends and a 
discussion of their reported relationship with major birth defects in the NBDPS. Maternal 
race/ethnicity was selected and assessed because it is strongly associated with study site and 
might have been impacted by changes in the study sites and because it might be associated 
with other exposures of interest (Siega-Riz et al., 2009, Ma et al., 2010, Glidewell et al., 
2014). Obesity was selected because it is one of the strongest and most consistent risk 
factors for many major birth defects, and obesity prevalence in the United States has 
increased over the time period of the study (Waller et al., 2007, Stothard et al., 2009, Flegal 
et al., 2012). Folic acid-containing multivitamins were selected for assessment because of 
the existing Public Health Service recommendation that all women capable of becoming 
pregnant consume at least 400 micrograms of folic acid daily (Houk et al., 1992). 
Medications are a strong focus of NBDPS because they provide an opportunity for safer 
medication use choices just before and during pregnancy, therefore we selected three 
medications of interest for the trend analysis either due to concerns about risk for major birth 
defects (opioids), rising use among reproductive aged women and some reports of fetal 
effects (SSRIs), and some reports of concern coupled with a transition from prescription to 
over-the-counter status (loratadine) (Centers for Disease Control and Prevention, 2004, 
Alwan et al., 2007, Gilboa et al., 2009, Broussard et al., 2011).
The study population for the time trend analysis was limited to mothers of control infants 
with an expected date of delivery (EDD) from January 1, 1998 through December 31, 2011. 
Mothers of control infants with an EDD between October 1, 1997 and December 31, 1997 
were excluded from this analysis due to the small sample size in 1997. Participants from 
New Jersey included mothers with EDDs from 1998–2002; North Carolina and Utah 
participants included mothers with EDDs after January 1, 2003. The maternal interviews of 
case-infants were excluded from this analysis because the association between certain 
exposures and birth defects outcomes might affect the exposure prevalence and trends.
Mothers participated in a computer-assisted telephone interview (CATI), which included 
questions regarding pregnancy history, demographics, and exposures that occurred from 
three months before conception through the end of the pregnancy. Mothers were interviewed 
in English or Spanish between six weeks and 24 months after their EDD, with a mean of 
approximately 9.5 months. In 2005, the CATI underwent a major revision to the content and 
order of the questions; the post-2005 CATI was implemented for births that occurred on or 
after January 1, 2006. For example, in the post-2005 CATI a new section on stress was 
added and two questions were added to the section on maternal high blood pressure to better 
distinguish pregnancy-related and chronic hypertension. Other questions, such as questions 
on the use and source of water, were substantially reduced and reformatted. Minor changes 
in wording or interviewer prompts were made throughout the study period. During the entire 
study period the interview participation rate was approximately 64% for control mothers. 
Participation rates for control mothers fluctuated over time, ranging from a high of 76% for 
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2000 EDDs to a low of 59% for 2010 EDDs; participation rates for 2011 EDDs were 
slightly lower (54%) due to a shorter time for follow-up, as the final interviews were 
conducted in March 2013.
For this analysis, obesity was defined as a pre-pregnancy body mass index (BMI) of ≥ 30 
kg/m2 (National Heart Lung and Blood Institute, 2000). Mothers reported height and weight 
and then BMI was later calculated from her responses. In the first several years of data 
collection, participants were only able to report height in feet and inches; if a mother was 
only able to report her height in centimeters, this was noted by the interviewer in the 
comments, and was then extracted and included in the BMI calculation (Razzaghi et al., 
submitted). Mothers with a calculated BMI of < 10 or > 70 kg/m2 were considered “out of 
range” and set to missing.
The NBDPS collected data on the frequency, duration, and timing of medication use for the 
exposure window of three months prior to pregnancy through the end of pregnancy. Mothers 
were asked about specific medical conditions and their treatment, as well as a specific list of 
medications, and about the use of fertility treatments. Mothers could also report use of any 
other medication that she was not explicitly asked about. Several medications were added to 
the specific list of medications in the post-2005 CATI, for example Claritin® (loratadine) 
and Celexa® (citalopram). For this analysis, we examined use of opioid-, SSRI-, and 
loratadine-containing medications at any time in pregnancy, which was defined as any self-
reported use from the month prior to conception through the end of the pregnancy. We also 
examined use of specific opioids (codeine, hydrocodone) and SSRIs (citalopram, fluoxetine, 
paroxetine, sertraline). The month prior to the pregnancy is included in our exposure 
window because of the difficulty in determining the exact date of conception and the likely 
errors in recall of specific dates of exposure, as well as the possibility of longer half-lives of 
some of the exposures possibly resulting in pregnancy exposures. In this analysis, folic acid-
containing multivitamin use was defined as any reported use of prenatal vitamins, 
supplements containing vitamin B complex, or any supplement with folic acid as a 
component during the month before pregnancy. This exposure window was chosen based on 
the Public Health Service recommendations for preconceptional use of folic acid for the 
prevention of neural tube defects.
The questions regarding maternal race/ethnicity were modified for the post-2005 CATI to be 
consistent with the National Center for Health Statistics’ categorization (Ingram et al., 
2003). In the earlier version of the CATI, mothers were asked “what is your race/ethnic 
group?” and were given the options to choose a single race/ethnicity or “other.” In the 
post-2005 CATI, in addition to asking the mothers their race/ethnic group, they received an 
interviewer prompt that they were able to select more than one category: American Indian or 
Alaska Native; Asian; Black or African American; Hispanic or Latina; Native Hawaiian or 
Other Pacific Islander; and White. For the time trend analysis of maternal race/ethnicity, we 
categorized this variable as non-Hispanic white, non-Hispanic black, Hispanic, and other/
mixed race/ethnicity, with non-Hispanic white mothers as the reference group.
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For the selected exposures, we examined the prevalence over time for all control mothers 
collectively, and stratified by race/ethnicity. Results were reported in two-year intervals, due 
to the small sample size of exposed mothers for some exposures, and to improve the stability 
of the estimates. For the time trend analysis, we used the non-parametric test statistic 
Kendall’s τβ, which evaluates monotonic trends in bivariate relationships (Kendall, 1948). 
We used exact procedures when cell counts were less than five. Because of the addition of 
the specific loratadine question in 2006, we also conducted a sub-analysis of the loratadine 
trend stratified by the CATI version (pre-2006 EDDs as compared to EDDs 2006 and later). 
All analyses were conducted using SAS version 9.3 (Cary, NC).
To put our results in context, we also reviewed all NBDPS manuscripts that examined one 
of these six variables, published through December 2014, and created a matrix summarizing 
the findings for the exposures of interest by categorizing them as all positive (dark red, 
vertical lines), some positive (light red, vertical lines), some negative (light blue, horizontal 
lines), all negative (dark blue, horizontal lines), or null (yellow, no lines) associations, or 
blank if the exposure-birth defects combination had not been published on yet.
RESULTS
There were 11,724 control mothers with EDDs from 1998–2011 who participated in the 
maternal interview. The mean maternal age at delivery was approximately 27 years. The 
interview was conducted in Spanish for 8.8% of interviewed mothers (n=1,032). The 
average time to interview was approximately 9.5 months.
The racial/ethnic distribution changed slightly during the study period, during which we 
observed a significant monotonic increase in the proportion of Hispanic mothers (20.7% to 
21.6%; p<0.01) and mothers reporting other/mixed race/ethnicity (4.1% to 13.7%; p<0.01), 
compared to non-Hispanic white mothers (Table 1). No significant monotonic time trend 
was noted for non-Hispanic black mothers.
Overall, approximately 18% of control mothers self-reported a pre-pregnancy height and 
weight that classified them as obese (Table 1). We observed a significant increase in the 
proportion of obese mothers over time, from 14% in 1998–1999 to 22% in 2010–2011 (p 
<0.01). This trend was observed for each of the race/ethnicity categories (p<0.01). Among 
non-Hispanic white mothers, the proportion of obese mothers increased marginally from 
14% in 1998–1999 to 19% in 2010–2011 (Figure 1a). The increase was greatest among non-
Hispanic black mothers, for whom the obesity prevalence increased from approximately 
20% in 1998–1999 to more than 33% by the end of the study period. The proportion of 
obese mothers increased 12 percentage points for Hispanic mothers and mothers of other/
mixed race/ethnicity.
Approximately 32.5% of all control mothers reported use of a folic acid-containing 
multivitamin during the month preceding conception, with a slight increase observed over 
time (27.1% in 1998–1999 to 38.9% in 2010–2011; p <0.01) (Table 1). Use of folic acid-
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containing multivitamins increased approximately 5–17% for mothers of most race/
ethnicities. We observed some variability for non-Hispanic black mothers (Figure 1b).
Overall, we did not observe a significant monotonic trend in the use of opioid analgesics 
during the study period (p=0.93) (Table 1). The only statistically significant monotonic trend 
in the use of opioids was an increase among mothers of other/mixed race/ethnicity between 
1998–1999 and 2010–2011 (p=0.03). However, we observed a spike in the prevalence of 
opioid use in 2004–2005 for non-Hispanic white mothers and non-Hispanic black mothers 
(Figure 1c). The increase in use in 2004–2005 was observed for use of hydrocodone-
containing medications, some of the most widely used opioids in this cohort, but was not 
observed for use of codeine-containing medications.
We observed an overall increase in the prevalence of use of SSRIs from 1998 to 2011 (Table 
1). This trend appears to be largely driven by the increase in the prevalence of use among 
non-Hispanic white mothers (p<0.01) and mothers of other/mixed race/ethnicity (p<0.01); 
there was no significant monotonic change in the prevalence of use among non-Hispanic 
black or Hispanic mothers (p=0.84 and p=0.56, respectively) (Figure 1d). The prevalence of 
use of sertraline increased slightly during the study period (1.0% in 1998–1999 to 2.8% in 
2010–2011). For citalopram there also appears to be an increase, albeit not statistically 
significant. For fluoxetine and paroxetine no clear trend was observed.
The prevalence of use of loratadine among all control mothers appears to have roughly 
doubled during the study period, from 3.6% in 1998–1999 to 6.3% in 2010–2011 (p<0.01) 
(Table 1). The overall increase in prevalence was observed for all mothers except for 
Hispanic mothers (Figure 1e). However, in sub-analyses stratifying by the CATI version 
significant trends were no longer observed.
The six exposures selected for the trend analysis have been studied in association with 58 
birth defects categories by NBDPS collaborators to date. The results from the analyses are 
summarized (Figure 2). For BMI, 19 of the 40 birth defects categories examined were noted 
to have a significant positive association with pre-pregnancy obesity. Gastroschisis was 
significantly associated with a low BMI. There were eight birth defects categories (of 33) 
with significant positive associations with use of opioids and three defect groups (of 24) 
significantly associated with use of SSRIs. There were 23 significant negative associations 
(some with overlapping case groups) between birth defects and use of folic acid-containing 
multivitamins. Results for use of loratadine and maternal race/ethnicity were inconsistent, 
with both significant positive and negative associations reported.
DISCUSSION
The NBDPS has made a major contribution to our understanding of the risk associated with 
a broad range of maternal exposures in early pregnancy. Some of these exposures have 
experienced changes over the course of the study that heighten the significance of their 
potential role in birth defects etiology. Over the 14 year period of NBDPS interviews, the 
prevalence of obesity among control mothers increased significantly as did the use of folic 
acid-containing multivitamins, SSRIs, and loratadine. No remarkable monotonic change in 
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the reported use of opioid medications was observed. The proportion of Hispanic mothers 
and mothers of other/mixed race/ethnicity increased during the study period; the proportion 
of non-Hispanic white mothers decreased during the study period.
The exposure prevalence trends we observed may be partly explained by factors external to 
the study, such as changing demographic characteristics of the source populations, or 
internal factors, such as changes to the CATI. The racial/ethnic distribution of NBDPS 
control mothers was similar to the distribution of pregnant women who participated in the 
National Health and Nutrition Examination Survey (NHANES) from 2001–2006, which was 
comprised of 55.9% non-Hispanic white women, 16.9% non-Hispanic black, 17.0% 
Mexican American, and 10.2% women who reported other race/ethnicity (Mirel et al., 
2009). However, comparing the racial/ethnic distribution in the NBDPS with NHANES is 
somewhat limited by the oversampling of pregnant women in NHANES, which resulted in a 
slightly higher proportion of Mexican American women and a lower proportion of non-
Hispanic white women in the pregnant cohort than was observed in the non-pregnant cohort. 
Based on birth certificate data, the trends in race and ethnicity distribution we observed in 
the NBDPS were comparable to national trends during this time period (Martin et al., 2015). 
In 2011, approximately 76.4% of infants in the United States were born to white mothers as 
compared to 79.2% in 1997; 23.2% of infants were born to Hispanic mothers in 2011 as 
compared to 18.3% in 1997. The obesity trend we observed was also similar to national 
estimates of an increase in the prevalence of pre-pregnancy obesity from 17.6% in 2003 to 
20.5% in 2009, using data from the Pregnancy Risk Assessment Monitoring System (Fisher 
et al., 2013). Similarly, the trend in use of SSRIs that we observed appears to reflect the 
overall increase in use of antidepressants during pregnancy in the United States and in 
Europe, which has been partly attributed to the increase in use for conditions other than 
depression (Cooper et al., 2007; Andrade et al., 2008; Harman et al., 2009). A decrease in 
use of paroxetine, however, has been noted in the United States following the release of the 
FDA warnings (Meunier et al., 2013). The observed trend in use of folic acid-containing 
multivitamins also appears to mirror the overall slight increase in use of folic acid-
containing supplements among women of childbearing age in the United States, which has 
been partly attributed to the increase in national interest in prevention of neural tube defects 
(Centers for Disease Control and Prevention, 2008). We did not observe a clear pattern in 
use of opioid analgesics during pregnancy. There does not appear to be a consistent trend in 
use in other studies, as some studies have reported an increase in the prevalence of opioid 
use among pregnant women while others have observed a decrease in use (Bateman et al., 
2014; Maeda et al., 2014). The interview participation rate among control mothers generally 
declined during the study period, which could affect the exposure prevalence trends and 
potentially be a source of bias. In a 2009 study of control mothers (1997–2003 EDDs), 
researchers found that NBDPS control mothers were generally representative of their base 
population, but the difference in distributions for certain characteristics, such as maternal 
race/ethnicity, was associated with participation (Cogswell et al., 2009).
Some observed changes in exposure are possible artifacts of the study protocol. For 
example, the trend in use of loratadine appears to be at least partially related to the addition 
of a question in the CATI explicitly asking about use of the medication. Although NBDPS 
exposure data are limited by maternal self-report and are potentially subject to recall bias, 
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prior studies have indicated that asking mothers about specific medications may help with 
maternal recall of medication use during pregnancy (Mitchell et al., 2011). In addition, 
loratadine moved from prescription to over-the-counter status in 2002, which might have 
impacted use (Food and Drug Administration, 2002). Investigators who want to assess the 
relationship between loratadine and birth defects should consider stratifying their analyses 
by year of EDD.
With changes in the NBDPS Centers over the 14 year period, some changes in catchment 
areas within the study sites, and the change in the race/ethnicity questions, we anticipated a 
noticeable change in the racial/ethnic distribution during the study period. Although these 
are possible explanations for the changes that were observed, overall, there was not a 
dramatic shift in this distribution. This provided some reassurance that the change in study 
sites did not have as much of an impact on the maternal race/ethnicity distribution as was 
anticipated.
NBDPS authors have published several papers examining the relationship birth defects and 
the exposures selected for this analysis. Several analyses investigating a spectrum of 
potential risk factors for specific birth defects have included race/ethnicity. In a 2007 study 
of factors associated with hypospadias, using NBDPS data from 1997–2000, researchers 
found sons of Hispanic mothers were at less risk of hypospadias than those of non-Hispanic 
white mothers (Carmichael et al., 2007). In a more recent follow-up to this study (1997–
2009 EDDs), researchers observed a decreased risk of second-degree hypospadias among 
sons of mothers of Hispanic or Asian/Pacific Islander race/ethnicity, but an increased risk of 
third-degree hypospadias among offspring of mothers of Asian/Pacific Islander or non-
Hispanic black race/ethnicity (Groen in ‘t Woud et al., 2014). Infants born to mothers of 
non-Hispanic black race/ethnicity have also been observed to be at increased risk of biliary 
atresia (1997–2002 EDDs) but a decreased risk of gastroschisis (1997–2003 EDDs) (The et 
al., 2007; Bird et al., 2009). No significant association with maternal race/ethnicity was 
observed in a 2010 spectrum analysis of factors associated with non-syndromic 
holoprosencephaly (Miller et al., 2010).
Studies examining the relationship between pre-pregnancy BMI and birth defects have 
mostly focused on the potential role of obesity. In 2007, using NBDPS data from 1997–
2002, Waller et al. found a significant association between maternal obesity and spina 
bifida, heart defects (all phenotypes combined), anorectal atresia, hypospadias, limb 
reduction defects, diaphragmatic hernia, and omphalocele; the odds ratio for the association 
between obesity and gastroschisis was below unity (Waller et al., 2007). In a 2008 study 
(1997–2003 EDDs) focusing on bilateral renal agenesis/hypoplasia, researchers observed a 
significant association with maternal obesity (Slickers et al., 2008). In a follow-up to the 
Waller et al. study, using data from 1997–2003, researchers examined the relationship 
between BMI and gastroschisis combined with the effect of maternal age, finding 
gastroschisis to be associated with low maternal age and low pre-pregnancy BMI (Siega-Riz 
et al., 2009). Although not statistically significant, a slightly elevated odds ratio was 
observed for the association between obesity and craniosynostosis (1997–2005 EDDs) 
(Boulet et al., 2010). Offspring of overweight and obese mothers have also been observed to 
be at increased risk of specific heart defects, including tetralogy of Fallot, total anomalous 
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pulmonary venous return, hypoplastic left heart syndrome, pulmonary valve stenosis, and 
secundum atrial septal defect, using NBDPS data from 1997–2004 (Gilboa et al., 2010).
In 2009, researchers used NBDPS data from 1998–2003 to examine rates of neural tube 
defects among pregnancies conceived after folic acid fortification of the food supply 
(Mosley et al., 2009). The researchers found little evidence of an association between folic 
acid supplement use and neural tube defects. In a study that examined the joint effects of 
maternal obesity and folic acid intake in association with microtia (1997–2005 EDDs), 
researchers found a decreased risk of microtia in non-obese women that reported 
periconceptional intake of folic acid-containing supplements (Ma et al., 2010). Similarly, in 
a study on the association of birth defects with folic acid supplementation and diabetes, 
using data from 1997–2004, researchers concluded that the lack of supplementation may be 
associated with an excess risk of birth defects in diabetic mothers (Correa et al., 2012).
As of December 1, 2014, investigators have published 42 articles using NBDPS data to 
examine associations between medication use in pregnancy and birth defects. In one of the 
earliest publications, there was no evidence of an increased risk of second- or third-degree 
hypospadias in association with use of loratadine (Centers for Disease Control and 
Prevention, 2004). In a study using NBDPS data from 1997–2003, researchers observed a 
significant positive association between loratadine and transverse limb deficiency, as well as 
a significant negative association with orofacial clefts (Gilboa et al., 2009). In a 2007 study 
of the association between SSRI use and birth defects, which used NBDPS data from 1997–
2002, researchers found significant associations between SSRIs and anencephaly, 
craniosynostosis, and omphalocele (Alwan et al., 2007). Also in 2011, researchers found use 
of opioid analgesics to be associated with an increased risk of several heart defects, 
including atrioventricular septal defects, and hypoplastic left heart syndrome, as well as 
spina bifida and gastroschisis (Broussard et al., 2011).
NBDPS reports have contributed substantially to the understanding of the birth defects risk 
of a broad range of exposures. Investigating risk factors and possible protective factors for 
birth defects remains of public health importance, as birth defects are the leading cause of 
infant mortality in the United States, and the etiology of most birth defects remains unclear 
(Nelson and Holmes, 1989; Petrini et al., 2002, Mathews et al., 2013). Long-term, 
population-based case-control studies continue to be an effective way to assess these 
associations and provide guidance to healthcare providers and the women they are treating. 
However, researchers involved in these studies should consider the internal and external 
factors that influence exposure prevalence over the course of a long-term study and consider 
updating early analyses after additional data are collected.
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Trends in selected maternal pregnancy exposures, stratified by race/ethnicity among control 
mothers in the National Birth Defects Prevention Study, 1998–2011. a) obesity; b) use of 
folic acid-containing multivitamins during the month prior to pregnancy; c) use of opioid 
analgesic medication during the month prior to pregnancy through the end of pregnancy; d) 
use of selective serotonin reuptake inhibitor medications during the month prior to 
pregnancy through the end of pregnancy; e) use of loratadine during the month prior to 
pregnancy through the end of pregnancy
Dawson et al. Page 13














Graphical summary of published results from the National Birth Defects Prevention Study, 
published 2004 – December, 2014, for associations between a spectrum of birth defects and 
selected maternal demographic characteristics and pregnancy exposures, including maternal 
pre-pregnancy body mass index (Waller et al., 2007; Slickers et al., 2008; Siega-Riz et al., 
2009; Boulet et al., 2010; Gilboa et al., 2010), use of folic acid-containing multivitamins 
(Mosley et al., 2009; Ma et al., 2010; Correa et al., 2012), opioid analgesics (Broussard et 
al., 2011), selective serotonin reuptake inhibitors (Alwan et al., 2007), loratadine (Centers 
for Disease Control and Prevention, 2004; Gilboa et al., 2009), and race/ethnicity 
Dawson et al. Page 14













(Carmichael et al., 2007; The et al., 2007; Bird et al., 2009; Miller et al., 2010; Groen in 't 
Woud et al., 2014).
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